FGFR2 is altered in 2.22% of malignant solid tumor patients with FGFR2 Mutation present in 1.63% of all malignant solid tumor patients [4].

FGFR2 Mutation is an inclusion criterion in 25 clinical trials for malignant solid tumor, of which 19 are open and 6 are closed. Of the trials that contain FGFR2 Mutation and malignant solid tumor as inclusion criteria, 7 are phase 1 (2 open), 6 are phase 1/phase 2 (5 open), 10 are phase 2 (10 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [5].

FGFR2 is altered in 2.84% of urothelial carcinoma patients with FGFR2 Mutation present in 2.32% of all urothelial carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 9 clinical trials for urothelial carcinoma, of which 9 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and urothelial carcinoma as inclusion criteria, 5 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [5].

FGFR2 is altered in 1.17% of non-small cell lung carcinoma patients with FGFR2 Mutation present in 1.02% of all non-small cell lung carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 6 are open and 2 are closed. Of the trials that contain FGFR2 Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 6 are phase 2 (5 open) [5].

FGFR2 is altered in 10.72% of cholangiocarcinoma patients with FGFR2 Mutation present in 3.48% of all cholangiocarcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 7 clinical trials for cholangiocarcinoma, of which 7 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

FGFR2 is altered in 2.39% of breast carcinoma patients with FGFR2 Mutation present in 1.02% of all breast carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FGFR2 Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (1 open) and 2 are phase 2 (2 open) [5].

FGFR2 is altered in 2.11% of cancer patients with FGFR2 Mutation present in 1.55% of all cancer patients [4].

FGFR2 Mutation is an inclusion criterion in 4 clinical trials for cancer, of which 1 is open and 3 are closed. Of the trials that contain FGFR2 Mutation and cancer as inclusion criteria, 4 are phase 2 (1 open) [5].

FGFR2 is altered in 9.95% of endometrial carcinoma patients with FGFR2 Mutation present in 9.67% of all endometrial carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

FGFR2 is altered in 2.32% of bladder carcinoma patients with FGFR2 Mutation present in 1.92% of all bladder carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Mutation and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.73% of colorectal carcinoma patients with FGFR2 Mutation present in 1.51% of all colorectal carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

FGFR2 is altered in 4.96% of gastric carcinoma patients with FGFR2 Mutation present in 1.43% of all gastric carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.39% of squamous cell lung carcinoma patients with FGFR2 Mutation present in 1.31% of all squamous cell lung carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [5].

FGFR2 is altered in 0.86% of sarcoma patients with FGFR2 Mutation present in 0.61% of all sarcoma patients [4].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Mutation and sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 is altered in 3.63% of adenocarcinoma of the gastroesophageal junction patients with FGFR2 Mutation present in 0.56% of all adenocarcinoma of the gastroesophageal junction patients [4].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FGFR2 is altered in 0.88% of pancreatic carcinoma patients with FGFR2 Mutation present in 0.46% of all pancreatic carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

FGFR2 Mutation is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

FGFR2 is altered in 6.23% of melanoma patients with FGFR2 Mutation present in 5.88% of all melanoma patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

FGFR2 is altered in 16.88% of intrahepatic cholangiocarcinoma patients with FGFR2 Mutation present in 4.95% of all intrahepatic cholangiocarcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for intrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 1.85% of head and neck squamous cell carcinoma patients with FGFR2 Mutation present in 1.69% of all head and neck squamous cell carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

FGFR2 is altered in 5.0% of gastric adenocarcinoma patients with FGFR2 Mutation present in 1.44% of all gastric adenocarcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.56% of head and neck carcinoma patients with FGFR2 Mutation present in 1.42% of all head and neck carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.61% of glioblastoma patients with FGFR2 Mutation present in 1.0% of all glioblastoma patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 1.56% of non-hodgkin lymphoma patients with FGFR2 Mutation present in 0.97% of all non-hodgkin lymphoma patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 is altered in 1.53% of ovarian carcinoma patients with FGFR2 Mutation present in 0.96% of all ovarian carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.53% of anaplastic astrocytoma patients with FGFR2 Mutation present in 0.44% of all anaplastic astrocytoma patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 0.11% of gastrointestinal stromal tumor patients with FGFR2 Mutation present in 0.11% of all gastrointestinal stromal tumor patients [4].

FGFR2 Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 Mutation and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [5].

FGFR2 is altered in 7.46% of malignant uterine neoplasm patients with FGFR2 Mutation present in 7.09% of all malignant uterine neoplasm patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 3.89% of anaplastic oligodendroglioma patients with FGFR2 Mutation present in 3.89% of all anaplastic oligodendroglioma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 10.72% of bile duct carcinoma patients with FGFR2 Mutation present in 3.48% of all bile duct carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 3.03% of nasal cavity and paranasal sinus carcinoma patients with FGFR2 Mutation present in 3.03% of all nasal cavity and paranasal sinus carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 6.57% of malignant hepatobiliary neoplasm patients with FGFR2 Mutation present in 2.26% of all malignant hepatobiliary neoplasm patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 3.37% of ganglioglioma patients with FGFR2 Mutation present in 2.25% of all ganglioglioma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 6.55% of hepatobiliary neoplasm patients with FGFR2 Mutation present in 2.25% of all hepatobiliary neoplasm patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 2.17% of oropharyngeal carcinoma patients with FGFR2 Mutation present in 2.17% of all oropharyngeal carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 2.48% of bladder urothelial carcinoma patients with FGFR2 Mutation present in 2.04% of all bladder urothelial carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

FGFR2 is altered in 2.01% of lip and oral cavity carcinoma patients with FGFR2 Mutation present in 1.76% of all lip and oral cavity carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.7% of cervical carcinoma patients with FGFR2 Mutation present in 1.51% of all cervical carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 2.04% of esophageal squamous cell carcinoma patients with FGFR2 Mutation present in 1.36% of all esophageal squamous cell carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 3.39% of esophageal carcinoma patients with FGFR2 Mutation present in 1.3% of all esophageal carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 2.47% of malignant laryngeal neoplasm patients with FGFR2 Mutation present in 1.23% of all malignant laryngeal neoplasm patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.73% of neuronal and mixed neuronal-glial tumors patients with FGFR2 Mutation present in 1.16% of all neuronal and mixed neuronal-glial tumors patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 1.15% of low grade glioma patients with FGFR2 Mutation present in 1.15% of all low grade glioma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 1.29% of malignant salivary gland neoplasm patients with FGFR2 Mutation present in 1.14% of all malignant salivary gland neoplasm patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.6% of diffuse glioma patients with FGFR2 Mutation present in 1.05% of all diffuse glioma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 1.46% of B-cell non-hodgkin lymphoma patients with FGFR2 Mutation present in 1.03% of all B-cell non-hodgkin lymphoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.17% of lung carcinoma patients with FGFR2 Mutation present in 1.02% of all lung carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.15% of small cell lung carcinoma patients with FGFR2 Mutation present in 0.96% of all small cell lung carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

FGFR2 is altered in 1.37% of glioma patients with FGFR2 Mutation present in 0.91% of all glioma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Mutation and glioma as inclusion criteria, 1 is phase 2 (0 open) [5].

FGFR2 is altered in 1.3% of lymphoma patients with FGFR2 Mutation present in 0.85% of all lymphoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

FGFR2 is altered in 1.42% of astrocytic tumor patients with FGFR2 Mutation present in 0.82% of all astrocytic tumor patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 1.08% of gallbladder carcinoma patients with FGFR2 Mutation present in 0.72% of all gallbladder carcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 1.31% of extrahepatic cholangiocarcinoma patients with FGFR2 Mutation present in 0.65% of all extrahepatic cholangiocarcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 0.88% of soft tissue sarcoma patients with FGFR2 Mutation present in 0.53% of all soft tissue sarcoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 is altered in 0.9% of pancreatic adenocarcinoma patients with FGFR2 Mutation present in 0.47% of all pancreatic adenocarcinoma patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 0.38% of histiocytic and dendritic cell neoplasm patients with FGFR2 Mutation present in 0.38% of all histiocytic and dendritic cell neoplasm patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 9.09% of low-grade neuroepithelial tumor, NOS patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 is altered in 0.2% of myeloproliferative neoplasm patients [4].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for non-muscle invasive bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and non-muscle invasive bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

FGFR2 Mutation is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 Mutation and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].